Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07221188 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Name: A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — clinical trial record (NCT07221188)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ZENITH-2

StatusRecruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2025-12-12

View on ClinicalTrials.gov ↗

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

Amendment history 2 changes detected by DataLookout

2026-07-28

Trial sites expanded: 43 → 53 locations

2026-04-17

Trial sites expanded: 6 → 43 locations

Trial Details

NCT Number	NCT07221188
Lead Sponsor	GlaxoSmithKline
Conditions	Non-alcoholic Fatty Liver Disease
Enrollment	1,250 participants
Start Date	2025-12-12
Primary Completion	2028-03-24 (estimated)
Study Completion	2028-03-24 (estimated)
Updated on ClinicalTrials.gov	2026-07-27